Combined Strategy of Mesenchymal Stem Cell Injection with Vascular Endothelial Growth Factor Gene Therapy for the Treatment of Diabetes-Associated Erectile Dysfunction

Xuefeng Qiu,Chao Sun,Wen Yu,Haocheng Lin,Zhaorui Sun,Yun Chen,Run Wang,Yutian Dai
DOI: https://doi.org/10.2164/jandrol.110.012666
2012-01-01
Andrology
Abstract:This study was designed to investigate the effect of vascular endothelial growth factor 164 adenovirus (Ad-VEGF(164))- transfected mesenchymal stem cells (MSC) on improving erectile function in diabetic rats. Forty-five male Sprague-Dawley rats were injected with streptozotocin to develop type 1 diabetes, whereas 10 served as normal controls. Diabetic rats were randomly divided into 3 groups: rats that underwent intracavernous injection with phosphate-buffered saline (DM+PBS), unmodified MSCs (DM+MSC), and Ad-VEGF164 transfected MSCs (DM+VMSC). Normal controls received intracavernous injection of PBS. Four weeks after injection, erectile function was measured by cavernous nerve electrostimulation. Penile tissue was harvested for histology and enzyme-linked immunoassay. Prior to injection, high expression of VEGF was confirmed in Ad-VEGF(164)-transfected MSCs by enzyme-linked immunoassay. Four weeks after injection, the erectile function, as well as the content of smooth muscle and endothelium in corpus cavernosum increased significantly in the MSC-injected groups compared with the DM+PBS group. There was a significant improvement of erectile function, the content of smooth muscle and endothelium, and the VEGF concentration in the corpus cavernosum in the DM+VMSC group compared with the DM+MSC group. Our study validates the effect of intracavernous injection of MSCs for diabetes-associated erectile dysfunction in an animal model. The combined strategy of MSC injection with VEGF gene therapy enhanced therapy of MSCs for the treatment of diabetes-associated erectile dysfunction.
What problem does this paper attempt to address?